As of May 27
| +0.24 / +2.20%|
The 10 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 21.00 and a low estimate of 9.00. The median estimate represents a +43.63% increase from the last price of 11.14.
The current consensus among 11 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.